Understanding how lung transplant recipients respond to vaccinations
Official title: Vaccination responses in lung transplant recipients
Funded at Stanford University · NIH-10892175 · Data updated 2026-11-12
This study is looking at how well lung transplant patients respond to COVID-19 vaccines, since they might not make enough antibodies, and it hopes to find better ways to protect them through improved vaccination strategies.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project start | August 5, 2022 |
| Project end | July 31, 2027 |
| Funding year | 2024 |
| Award (this year) | $412,076 |
| NIH project number | 5U01HL163124-03 |
| Project ID | NIH-10892175 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are lung transplant recipients who are immunocompromised and may have received COVID-19 vaccinations.
✕Less likely to help
Patients who have not undergone lung transplantation or those who are not immunocompromised may not benefit from this research.
What this research studies
This research investigates the immune responses of lung transplant recipients to vaccinations, particularly focusing on the COVID-19 mRNA vaccines. It aims to understand why these patients, who are often immunocompromised, may not produce adequate antibody responses after vaccination. By creating a biorepository of vaccine-related biological samples, the study will analyze the immune responses in detail, which could lead to improved vaccination strategies for this vulnerable population. The collaboration involves multiple institutions, including Stanford, to enhance the research's scope and impact.
Why it matters
Potential benefit: If successful, this research could lead to more effective vaccination strategies for lung transplant recipients, improving their protection against infections.
How similar studies have gone: Previous studies have indicated challenges in vaccine responses among transplant recipients, suggesting that this research is addressing a critical and underexplored area.
Where this research is happening
-
Stanford University
Stanford, United States Active
Researchers
- Principal investigator: Nicolls, Mark Robert — Stanford University
- Study coordinator: Nicolls, Mark Robert
Related research
Other NIH-funded projects on the same topics.
-
Vaccination responses in lung transplant patients
This grant studies how people who have received lung transplants respond to COVID-19 vaccines and why their antibody responses may be limited.
-
Vaccine responses in people with lung transplants
This project looks at how well COVID-19 vaccines trigger immune protection in people who have had lung transplants.
-
Exercise-based frailty program for people awaiting lung transplants
A tailored exercise and lifestyle program is being tested to reduce frailty and improve outcomes for people waiting for a lung transplant.
-
Understanding why a lung transplant sometimes fails early and how to tailor treatment
A study of people receiving lung transplants to find molecular differences that cause early graft failure and point to better, personalized therapies.
-
Targeting inflammation and alloimmunity in lung transplant recipients with clazakizumab
A study to see if blocking IL-6 with clazakizumab can improve survival and reduce rejection in people who have received a lung transplant.
-
The Post-Lung Transplant Aging in Immune Cells in Donor Lungs
This grant explores how aging donor lungs affect lung transplant outcomes by studying immune cells called alveolar macrophages.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.